MedTrace Logo

CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS

NCT03291444 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-03-15

No results posted yet for this study

Summary

The main purpose of this study is to verify the safety and potential effectiveness of CART cells combined with peptide specific dendritic cell in relapsed/refractory leukemia.

Conditions

Interventions

BIOLOGICAL

Chimeric antigen receptor T cells

After pretreatment, chimeric antigen receptor T cells will be transfused.

BIOLOGICAL

peptide specific dendritic cell

After transfusion of chimeric antigen receptor T cells, Eps8 or WT1 peptide specific dendritic cell were intradermal injected.

Sponsors & Collaborators

  • Shenzhen Geno-Immune Medical Institute

    collaborator OTHER

  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

    collaborator OTHER

  • Zhujiang Hospital

    lead OTHER

Principal Investigators

  • Yuhua Li, M.D, Ph.D · Zhujiang Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-05
Primary Completion
2024-12-31
Completion
2025-06-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03291444 on ClinicalTrials.gov